ASPH.F Stock Overview A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ascentage Pharma Group International Competitors Price History & Performance
Summary of share price highs, lows and changes for Ascentage Pharma Group International Historical stock prices Current Share Price HK$6.45 52 Week High HK$6.45 52 Week Low HK$2.35 Beta 1.13 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change n/a Change since IPO 5.74%
Recent News & Updates
Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025 Jan 02 Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million. Dec 28
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08 See more updates
Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025 Jan 02 Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million. Dec 28
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08
Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration Aug 13
Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024 Aug 09
Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351) Jun 18
Ascentage Pharma Group International Announces Board and Committee Changes Jun 13 Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting May 25 Ascentage Pharma Group International, Annual General Meeting, May 10, 2024 Mar 28
Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting Mar 06
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia Feb 14
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN) Jan 17
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib Dec 15
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR Dec 11
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication Nov 25
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients Nov 18 Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports
Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc Oct 24
Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia Oct 18
Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE Oct 13
Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial Aug 22 Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax Aug 08
Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All) Jul 06
Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC Jun 06
Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST Jun 01
Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting May 29 Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million. Feb 02
Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List Jan 19 Shareholder Returns ASPH.F US Biotechs US Market 7D 0% -1.9% -2.8% 1Y n/a -5.7% 24.1%
See full shareholder returns
Return vs Industry: Insufficient data to determine how ASPH.F performed against the US Biotechs industry .
Return vs Market: Insufficient data to determine how ASPH.F performed against the US Market .
Price Volatility Is ASPH.F's price volatile compared to industry and market? ASPH.F volatility ASPH.F Average Weekly Movement n/a Biotechs Industry Average Movement 10.9% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ASPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ASPH.F's volatility change over the past year.
About the Company Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.
Show more Ascentage Pharma Group International Fundamentals Summary How do Ascentage Pharma Group International's earnings and revenue compare to its market cap? ASPH.F fundamental statistics Market cap US$1.74b Earnings (TTM ) -US$49.36m Revenue (TTM ) US$123.71m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ASPH.F income statement (TTM ) Revenue CN¥903.03m Cost of Revenue CN¥27.45m Gross Profit CN¥875.58m Other Expenses CN¥1.24b Earnings -CN¥360.28m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -1.16 Gross Margin 96.96% Net Profit Margin -39.90% Debt/Equity Ratio 216.3%
How did ASPH.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 06:25 End of Day Share Price 2024/10/17 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ascentage Pharma Group International is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yang Huang BofA Global Research Jin Zhang China International Capital Corporation Limited Wangbin Zhou China International Capital Corporation Limited
Show 10 more analysts 